Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
18(60%)
Results Posted
100%(4 trials)
Terminated
2(7%)

Phase Distribution

Ph early_phase_1
3
10%
Ph phase_1
5
17%
Ph phase_3
7
23%
Ph not_applicable
1
3%
Ph phase_2
9
30%
Ph phase_4
4
13%

Phase Distribution

8

Early Stage

9

Mid Stage

11

Late Stage

Phase Distribution29 total trials
Early Phase 1First-in-human
3(10.3%)
Phase 1Safety & dosage
5(17.2%)
Phase 2Efficacy & side effects
9(31.0%)
Phase 3Large-scale testing
7(24.1%)
Phase 4Post-market surveillance
4(13.8%)
N/ANon-phased studies
1(3.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

18

trials recruiting

Total Trials

30

all time

Status Distribution
Active(18)
Completed(4)
Terminated(4)
Other(4)

Detailed Status

Recruiting10
Active, not recruiting8
unknown4
Completed4
Terminated2
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
30
Active
18
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (10.3%)
Phase 15 (17.2%)
Phase 29 (31.0%)
Phase 37 (24.1%)
Phase 44 (13.8%)
N/A1 (3.4%)

Trials by Status

terminated27%
unknown413%
active_not_recruiting827%
withdrawn27%
recruiting1033%
completed413%

Recent Activity

Clinical Trials (30)

Showing 20 of 30 trialsScroll for more
NCT06016465Early Phase 1

Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?

Recruiting
NCT07402707Phase 4

Dosing of Steroids for Acute Asthma Given in the Emergency Department - a Pilot Randomised Feasibility Trial of Dexamethasone in Children

Recruiting
NCT05721027Phase 4

Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.

Recruiting
NCT06331520Phase 3

NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

Completed
NCT04756726Phase 1

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Active Not Recruiting
NCT04151667Phase 2

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Active Not Recruiting
NCT05986318Phase 2

Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung Disease

Recruiting
NCT04303065Phase 3

Trial of Dexamethasone for Traumatic Brain Injured Patients With Brain Contusions and Pericontusional Edema

Terminated
NCT05028348Phase 3

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Active Not Recruiting
NCT06974604Phase 2

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

Recruiting
NCT06259006Phase 3

TREAT-SC: Early, Short Course Oral Dexamethasone for the Treatment of Sydenham Chorea in Children

Recruiting
NCT04891809Phase 2

Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

Active Not Recruiting
NCT04998786Phase 2

A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Active Not Recruiting
NCT04717700Phase 2

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active Not Recruiting
NCT06616142Phase 1

Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate

Recruiting
NCT05996406Phase 2

Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)

Active Not Recruiting
NCT04782687Phase 2

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Active Not Recruiting
NCT03523221Phase 1

Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis

Recruiting
NCT06126354Phase 1

Dexamethasone/Pancreatic Clamp P&F

Withdrawn
NCT06479317Not Applicable

The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
30